Human papillomavirus testing in primary cervical screening - PubMed (original) (raw)
Human papillomavirus testing in primary cervical screening
J Cuzick et al. Lancet. 1995.
Abstract
Several studies have examined the role of tests for human papillomavirus (HPV) in screening for cervical cancer but as yet the relevance is unclear. We looked at HPV testing for types 16, 18, 31, and 33 on material taken at the time of a cervical smear in 2009 eligible women having routine screening. Women with any degree of dyskaryosis or high levels of one of these HPV types were referred for colposcopy. 44% of the cervical intraepithelial neoplasia (CIN) lesions of grade 2/3 detected had negative cytology and were found only by HPV testing. A further 22% of the CIN 2/3 lesions were positive for HPV but showed only borderline or mild cytological changes. The positive predictive value of HPV testing was 42%, which was similar to that for moderate dyskaryosis. HPV types 16 and 31 were more sensitive and specific for CIN 2/3 than were types 18 or 33. However, 25% of the CIN 2/3 lesions were not detected by these four HPV tests. We suggest that HPV testing could usefully augment but not replace conventional cytology. These results should stimulate a much larger randomised trial to assess the impact of these improved CIN 2/3 detection rates on the subsequent incidence of invasive cancer.
Comment in
- Human papillomavirus testing in primary cervical screening.
Sun XW, Koulos JP, Felix JC, Ferenczy A, Richart RM, Park TW, Wright TO Jr. Sun XW, et al. Lancet. 1995 Sep 2;346(8975):636. doi: 10.1016/s0140-6736(95)91466-8. Lancet. 1995. PMID: 7651020 No abstract available. - Human papillomavirus testing in cervical screening.
Torné A, Puig-Tintoré LM, Sánchez E. Torné A, et al. Lancet. 1995 Sep 16;346(8977):771-2. doi: 10.1016/s0140-6736(95)91528-1. Lancet. 1995. PMID: 7658887 No abstract available.
Similar articles
- HPV testing in primary screening of older women.
Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P. Cuzick J, et al. Br J Cancer. 1999 Oct;81(3):554-8. doi: 10.1038/sj.bjc.6690730. Br J Cancer. 1999. PMID: 10507785 Free PMC article. - Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O, Kares S, Kujala P, Tirkkonen M, Vuento R, Kholová I, Luukkaala T, Osuala V, Mäenpää J. Veijalainen O, et al. Acta Obstet Gynecol Scand. 2016 Nov;95(11):1220-1227. doi: 10.1111/aogs.13013. Acta Obstet Gynecol Scand. 2016. PMID: 27591407 - Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Kulasingam SL, et al. JAMA. 2002 Oct 9;288(14):1749-57. doi: 10.1001/jama.288.14.1749. JAMA. 2002. PMID: 12365959 - Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M. Koliopoulos G, et al. Cochrane Database Syst Rev. 2017 Aug 10;8(8):CD008587. doi: 10.1002/14651858.CD008587.pub2. Cochrane Database Syst Rev. 2017. PMID: 28796882 Free PMC article. Review. - [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Giorgi Rossi P. Ronco G, et al. Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33. Epidemiol Prev. 2012. PMID: 23139163 Review. Italian.
Cited by
- Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States.
Cuzick J, Adcock R, Kinney W, Castle PE, Robertson M, McDonald RM, Stoler MH, Du R, Wheeler CM; New Mexico HPV Pap Registry Steering Committee. Cuzick J, et al. Int J Cancer. 2023 Jul 1;153(1):83-93. doi: 10.1002/ijc.34519. Epub 2023 Apr 7. Int J Cancer. 2023. PMID: 36946690 Free PMC article. - Acceptability and Feasibility of HPV Self-Sampling as an Alternative Primary Cervical Cancer Screening in Under-Screened Population Groups: A Cross-Sectional Study.
Wong EL, Cheung AW, Wong AY, Chan PK. Wong EL, et al. Int J Environ Res Public Health. 2020 Aug 27;17(17):6245. doi: 10.3390/ijerph17176245. Int J Environ Res Public Health. 2020. PMID: 32867315 Free PMC article. - Improved Rates of Cervical Cancer Screening Among Transmasculine Patients Through Self-Collected Swabs for High-Risk Human Papillomavirus DNA Testing.
Goldstein Z, Martinson T, Ramachandran S, Lindner R, Safer JD. Goldstein Z, et al. Transgend Health. 2020 Mar 16;5(1):10-17. doi: 10.1089/trgh.2019.0019. eCollection 2020 Mar 1. Transgend Health. 2020. PMID: 32322684 Free PMC article. - Clinicopathologic significance and treatment of ASC-US in cervical cytology.
Abdulaziz AMA, Liu L, Sun Y, You X, Cui B, Han S, Zhang Y. Abdulaziz AMA, et al. Int J Clin Exp Pathol. 2020 Feb 1;13(2):307-316. eCollection 2020. Int J Clin Exp Pathol. 2020. PMID: 32211114 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical